- Home
- COMM vs AUPH Comparison
COMM vs AUPH Comparison
Compare COMM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COMM | AUPH |
|---|---|---|
| Founded | 1976 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 1.6B |
| IPO Year | 2013 | 1999 |
Fundamental Metrics
Financial Performance| Metric | COMM | AUPH |
|---|---|---|
| Price | $18.28 | $15.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $13.25 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 3.2M | 1.0M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.52 | 0.55 |
| Revenue | ★ $5,299,100,000.00 | $265,808,000.00 |
| Revenue This Year | $37.12 | $21.76 |
| Revenue Next Year | $3.19 | $16.45 |
| P/E Ratio | ★ $13.80 | $27.90 |
| Revenue Growth | ★ 33.82 | 20.62 |
| 52 Week Low | $2.94 | $6.55 |
| 52 Week High | $20.55 | $16.54 |
Technical Indicators
Market Signals| Indicator | COMM | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 44.46 |
| Support Level | $17.84 | $15.64 |
| Resistance Level | $18.32 | $15.98 |
| Average True Range (ATR) | 0.58 | 0.39 |
| MACD | -0.14 | -0.12 |
| Stochastic Oscillator | 22.30 | 20.26 |
Price Performance
Historical ComparisonAbout COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.